Halda Therapeutics - About the company
Halda Therapeutics is an acquired company based in New Haven (United States), founded in 2019 by Craig Crews. It operates as a Developer of precision therapeutics for cancer treatment. Halda Therapeutics has raised $217M in funding from investors like Connecticut Innovations, Elm Street Ventures and Canaan, with last known valuation of $*****. The company has 3250 active competitors, including 1119 funded and 771 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio.
Company Details
Developer of precision therapeutics for cancer treatment. It offers a lead drug candidate which is a RIPTAC therapeutic that utilizes androgen receptor as a targeting protein to selectively deliver the drug for the treatment of metastatic, castrate-resistant prostate cancer, and tumors.
- Website
- haldatx.com
- Social
- Email ID
- *****@haldathera.com
- Phone Number
- +1 **********
Key Metrics
Founded Year
2019
Location
New Haven, United States
Stage
Acquired
Total Funding
$217M in 4 rounds
Latest Funding Round
Last Known Valuation
$***** as on Nov 17, 2025
Investors
Ranked
59th among 3250 active competitors
Similar Companies
Exit Details
Acquired by Johnson & Johnson (Nov 17, 2025)
Legal entities associated with Halda Therapeutics
Halda Therapeutics is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
HALDA THERAPEUTICS INC. CIN: 832428365 , United States, Active | - | - | - |
Halda Therapeutics's acquisition details
Halda Therapeutics got acquired by Johnson & Johnson on Nov 17, 2025 at an acquisition amount of $*****.
Click here to take a look at Halda Therapeutics's acquisition in detail
Sign up to download Halda Therapeutics' company profile
Halda Therapeutics's funding and investors
Halda Therapeutics has raised a total funding of $217M over 4 rounds. Its first funding round was on Feb 28, 2019. Its latest funding round was a Series B round on Aug 12, 2024 for $*****. 10 investors participated in its latest round. Halda Therapeutics has 12 institutional investors.
Here is the list of recent funding rounds of Halda Therapeutics:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Aug 12, 2024 | 1950815 | Series B | 6452515 | 4182385 | 9337693 | 4362237 |
May 21, 2024 | 8034618 | Series B | 8623458 | 9341563 | 5874268 | 8493291 |
Dec 09, 2021 | 8547084 | Series B | 4280541 | 3913211 | 1086730 |
Access funding benchmarks and valuations. Sign up today!View details of Halda Therapeutics's funding rounds and investors
Halda Therapeutics' founders and board of directors
Founder? Claim ProfileThe founders of Halda Therapeutics is Craig Crews. Craig Crews is the CEO of Halda Therapeutics.
Here are the details of Halda Therapeutics' key team members:
- Craig Crews: Founder & CEO of Halda Therapeutics and founder of 1 other company. Contact Info: 1 email address
View details of Halda Therapeutics's Founder profiles and Board Members
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Halda Therapeutics's Competitors and alternates
Top competitors of Halda Therapeutics include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of Halda Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 75/100 | |
3rd | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 72/100 | |
5th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
6th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
7th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 71/100 | |
8th | Karyopharm 2008, Newton (United States), Public | Biopharmaceutical company focused on developing and commercializing innovative cancer therapies | $98.4M | 71/100 | |
9th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
10th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
59th |  Halda Therapeutics 2019, New Haven (United States), Acquired | Developer of precision therapeutics for cancer treatment | $217M | 65/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Halda Therapeutics's competitors? Click here to see the top ones
Halda Therapeutics's Investments and acquisitions
Halda Therapeutics has made no investments or acquisitions yet.
Reports related to Halda Therapeutics
Here is the latest report on Halda Therapeutics's geography:
News related to Halda Therapeutics
Filter this listMedia has covered Halda Therapeutics for a total of 10 events in the last 1 year, 5 of them have been about company updates and 1 about partnerships.
•
Johnson & Johnson Completes Acquisition of Halda Therapeutics for $3.05 BillionNew Jersey Business Magazine•Dec 31, 2025•Johnson & Johnson, Halda Therapeutics, Farmers & Merchants Bank
•
J&J Axes Eczema Drug from $1.25B AcquisitionEndpoints•Dec 26, 2025•Johnson & Johnson, Halda Therapeutics
•
•
•
VantAI Links With Halda in Potential $1B+ Proteomics PactBioSpace•Aug 19, 2025•Halda, VantAI, Halda Therapeutics
•
Halda Therapeutics Announces Appointment of Eyal Attar, MD, as Chief Medical OfficerBusiness Wire•Apr 22, 2025•Halda Therapeutics
•
Halda starts Phase 1/2 trial of HLD-0915 for metastatic prostate cancer.Business Wire•Feb 24, 2025•Halda Therapeutics
•
•
•
Halda Therapeutics Raises $126M in Series B Extension FinancingFinSMEs•Aug 12, 2024•Halda Therapeutics, Deep Track Capital, Frazier Life Sciences, RA Capital Management and 22 others
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Halda Therapeutics
Explore our recently published companies
- Elan Lifestyle - 2013 founded, Unfunded company
- Exborder - 2012 founded, Unfunded company
- Dwellerin - 2016 founded, Unfunded company
- Easetronics.com - 2004 founded, Unfunded company
- Edulabtech - Unfunded company
- Eduscanner.com - 2018 founded, Unfunded company
